Oppenheimer reiterated their outperform rating on shares of Catalyst Pharmaceuticals (NASDAQ:CPRX – Free Report) in a research report report published on Wednesday, Benzinga reports. They currently have a $29.00 price target on the biopharmaceutical company’s stock. A number of other equities research analysts have also weighed in on the company. Citigroup began coverage on Catalyst […]
CORAL GABLES, Fla., March 28, 2024 Catalyst Pharmaceuticals, Inc. , a commercial-stage, patient-centric biopharmaceutical company focused on in-licensing, developing, and commercializing novel.
Catalyst Pharmaceuticals Inc (NASDAQ:CPRX) recently witnessed an insider sell by Chief Compliance/Legal Officer Brian Elsbernd, according to a SEC Filing.
CORAL GABLES, Fla., March 27, 2024 (GLOBE NEWSWIRE) Catalyst Pharmaceuticals, Inc. ("Catalyst") (Nasdaq: CPRX), a commercial-stage biopharmaceutical company focused on in-licensing, developing, and commercializing novel medicines for patients living